Stockwinners Market Radar for November 13, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:25 EST Zeta Global says short-seller report 'riddled with misrepresentations' - Zeta Global issued the following statement in response to claims made in a report by Culper Research, a short-seller, published on November 13, 2024, stating: "Based upon Zeta's and its legal counsel's preliminary review and evaluation of the report, the Company believes this report is riddled with misrepresentations, speculative conjecture, and categorically false statements. The report is misleading and conveys, at most, a superficial understanding of Zeta's business and practices. It relies heavily on questionable sources that get basic facts wrong, cites financial metrics that are off by hundreds of millions of dollars, and doesn't even correctly identify the Company's Big Four auditor. We are providing the facts on the report's most egregious claims here: Zeta is confident in its internal accounting processes and controls. Zeta's independent auditor, Deloitte, performs annual audits of the Company's financial statements. Zeta is confident in its evaluation of contracts and the determination of revenue recognition in accordance with Generally Accepted Accounting Principles. On a quarterly basis, Zeta management briefs the Audit Committee of the Board of Directors on its relationships with customers who are also vendors. In the aggregate, revenue generated by Zeta's customer relationships that are also vendors is insignificant. The opinion from our independent auditors, Deloitte, related to Zeta's FY2023 financial statements was unqualified, as was the opinion on the Company's internal controls over financial reporting as of December 31, 2023. Zeta is confident in its data collection practices, policies and processes to ensure compliance with applicable laws. We do not operate so-called "consent farms". Zeta has made significant investments in its data protection, data governance, and privacy oversight and is regularly audited and reviewed by partners and clients. In addition, Zeta reviews the opt-in/opt-out processes and privacy policies of its data partners. Contrary to the report, the total contribution of Apptness and ArcaMax to Zeta's business is not material. Together, through the third quarter of 2024, their year-to-date revenue contribution is less than 3% and they make up less than 1% of Zeta's data assets. These contributions have trended down. As further evidence of the inaccuracies of the report, Digital Media Solutions is not a material customer or partner, as demonstrated by its trailing twelve-month revenue being less than $200,000 as of September 30, 2024."

19:50 EST InMed Pharmaceuticals Inc trading halted, news pending

18:55 EST Spectrum Brands raises quarterly dividend 12% to 47c from 42c per share - Spectrum Brands announced that its Board of Directors approved a 12% increase in its dividend payout, and declared a quarterly dividend of 47c per share on the common stock of the company. This new quarterly dividend rate represents an annualized dividend yield of 2% based on the closing stock price. The dividend is payable on December 17 to shareholders of record as of November 26.

18:47 EST Cisco CEO: We saw strong AI demand in Q1 - In an interview on CNBC's Mad Money, Chuck Robbins said cloud customers were strong in Q1, up triple digits year-over-year. The company is seeing success in backend networks, he noted. 57% of Cisco's revenue is now coming from recurring streams, which provides predictability, Robbins said. He feels that the subscription model allows the company to provide continuous innovation to customers.

18:32 EST Rhythm announces publication of setmelanotide Phase 3 results in The Lancet - Rhythm Pharmaceuticals announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor agonist, in children between the ages of 2 and younger than 5 years old with Bardet Biedl syndrome or pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency. The data are published in the peer-reviewed journal The Lancet Diabetes & Endocrinology. "Severe, early-onset obesity has been shown to have a negative short-term and long-term impact on a child's health," said Professor Jesus Argente, M.D., Ph.D., Department of Pediatrics and Pediatric Endocrinology, Hospital Infantil Universitario Nino Jesus and Universidad Autonoma de Madrid, Madrid, Spain. "In this study, setmelanotide demonstrated clinically meaningful reductions in hunger and body weight in patients younger than 5 years of age with severe obesity. We believe these data support the use of this targeted therapy in a patient population that could benefit from intervention as early as possible."

18:09 EST PTC Therapeutics' AADC deficiency gene therapy granted FDA approval - PTC Therapeutics announced that the FDA accelerated approval of its gene therapy for the treatment of AADC deficiency, the first-ever gene therapy approved in the U.S. that is directly administered to the brain. The gene therapy, which will be marketed in the U.S. with the brand name Kebilidi, is indicated for the treatment of children and adults with AADC deficiency, including the full spectrum of disease severity. Launch preparations are underway, with centers of excellence already identified and surgeons trained in the procedure to deliver the gene therapy. AADC deficiency is a highly morbid and life-shortening rare genetic disorder that results in the inability to synthesize dopamine, a neurotransmitter essential for motor function. Clinical trial results demonstrate that following gene therapy, de novo synthesis of dopamine occurs, followed by the progressive acquisition of motor development milestones. Along with the Biologics License Application approval, a Rare Disease Priority Review Voucher was granted. The company plans to monetize the voucher.

17:33 EST T-Mobile CEO sells $9.51M in common stock as part of option exercise - In a regulatory filing, In a regulatory filing, T-Mobile disclosed that its CEO Michael Sievert sold 40K shares of common stock on November 11th as part of option exercise in total transaction of $9.51M.

17:23 EST Oddity to repurchase 2.35M shares from L Catterton for $100M - Oddity announced that it has entered into a transaction with a fund managed by L Catterton to repurchase approximately 2.35M Class A Ordinary Shares of the company for a total cash consideration of approximately $100M, at a purchase price of $42.501 per share. The transaction is independent of the company's standing share buyback plan-announced on June 7 and authorizing the company to purchase up to $150M of the company's shares over three years-which will continue as planned subject to its terms, including the availability of distributable funds. After the closing of the transaction, L Catterton will own approximately 4M shares, representing approximately 7% of the company's ordinary shares outstanding as of September 30, 2024, pro forma for the transaction.

17:18 EST Bluejay Diagnostics announces 1-for-50 reverse stock split - Bluejay Diagnostics announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 18, and the company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 18 under the company's existing trading symbol, "BJDX." At such time, the company's common stock will also commence trading with a new CUSIP number, 095633509.

17:13 EST Northrop Grumman awarded $540.92M in Missile Defense Agency contract options - Northrop Grumman was awarded five, one-year, firm-fixed-price options under the active R&D Prototype Other Transaction Authority, or OTA, agreement with a value of $540.92M. This is an increase in dollar value of the current agreement from $291.86M to $832.78M. The R&D OTA agreement was competitively awarded through The Missile Defense Agency's, or MDA, authority under 10 U.S. Code4022. This effort is in accordance with MDA Press Release: 24-NEWS-0009 for Northrop Grumman to continue performance under their existing OTA agreement. Under this award, the performer will further develop and define its Glide Phase Interceptor design concept. The work will be performed in Chandler, Arizona, with an estimated completion date of November 2029. FY25 research, development, test and evaluation funds in the amount of $24.64M are being obligated at the time of award. MDA is the contracting activity.

17:06 EST Eli Lilly announces results from Phase 3 SURMOUNT-1 three-year study - Eli Lilly and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly reduced the risk of progression to type 2 diabetes in adults with pre-diabetes and obesity or overweight, compared with placebo, over 176 weeks. Tirzepatide demonstrated sustained average weight loss of 22.9% through the three-year treatment period for the efficacy estimand. These findings were published in The New England Journal of Medicine and recently presented at ObesityWeek 2024. "Individuals treated with tirzepatide lost on average up to 23% of their body weight and maintained this for over three years, while benefitting from a substantial decrease in risk of developing type 2 diabetes. In absolute terms, nearly 99% of individuals treated with tirzepatide remained diabetes-free at 176 weeks," said Ania Jastreboff, M.D., Ph.D., director of the Yale Obesity Research Center. "These results are impressive given the degree of sustained weight reduction and decrease in risk of diabetes."

17:01 EST Griffon COO Mehmel sells 8,697 common shares - In a regulatory filing, Griffon president and COO Robert Mehmel disclosed the sale of 8,697 common shares of the company on November 11 at a price of $70.10 per share.

16:35 EST Adaptimmune trading resumes

16:31 EST Tetra Tech falls 6% to $44.40 after Q4 results, initial FY25 outlook

16:26 EST DMC Global CEO Michael Kuta to retire - DMC Global announced Michael Kuta will retire as the company's president, CEO and as a member of the board, effective November 29. James O'Leary, DMC's executive chairman, has agreed to assume the role of interim president and CEO of the company upon Kuta's retirement. O'Leary joined the board in November 2023 with nearly four decades of executive leadership, finance, capital markets and board-level experience.

16:24 EST Itron and PG&E collaborate in EV charging innovation - Itron (ITRI) and PG&E (PG&E) are collaborating with the aim of making electric vehicle, or EV, charging more accessible and affordable for PG&E's customers. As part of exploring ways to modernize its electric meter network, PG&E is working with Itron on a customer-focused pilot to develop and test the management of EV charging loads in real-time, with the goal of significantly lowering the barrier for customers to charge their EV at home by avoiding the need for costly customer electric panel and service upgrades. A Level 2 charger is up to 15 times faster than plugging into a standard wall outlet and allows drivers to fill an all-electric vehicle from empty overnight. The EV Connect program uses distributed intelligence edge computing that operates on a customer's electric meter directly. This on-meter application connects to, and coordinates with, the customer's EV charger to keep charging within their panel and utility grid limits. The initial scope of the EV Connect pilot program will support up to 1,000 residential customers who currently own or are considering purchasing an EV and have panel or service limitations that prevent them from installing a Level 2 EV charger at home. PG&E and Itron plan to launch the new pilot offering in early 2025, with larger availability in the second half of 2025. Depending on learnings and the success of the pilot program, PG&E will evaluate extending the program to be broadly available on an ongoing basis.

16:20 EST Structure Therapeutics expects cash to fund operations through at least 2027 - Cash, cash equivalents and short-term investments totaled $915.3 million on September 30, 2024. The Company expects its current cash, cash equivalents and short-term investments to fund projected operations and key clinical milestones through at least 2027, including all GSBR-1290 studies for Phase 3 readiness but excluding Phase 3 registrational studies. "We are in a period of great momentum and execution at Structure Therapeutics, having begun our next phase of development with GSBR-1290," said Raymond Stevens, Ph.D., Founder and CEO of Structure Therapeutics. "The ACCESS and ACCESS II studies are designed to generate a comprehensive data set that we believe will provide additional insights into the differentiated profile of GSBR-1290 as a potential best-in-class oral small molecule GLP-1 receptor agonist. We also plan to declare our first oral small molecule amylin development candidate later this quarter. We look forward to 2025 as a pivotal year for Structure."

16:19 EST Dollar Tree announces leadership changes - Dollar Tree "announced several updates to its executive leadership team. These strategic shifts have been implemented to further position Dollar Tree and Family Dollar for success in the future. Steve Schumacher has been promoted to Executive Vice President and Chief People Officer, effective immediately. Schumacher, who has served as Interim Chief People Officer for the past six months, will continue to lead all Human Resources functions for the Dollar Tree and Family Dollar banners. Schumacher joined Dollar Tree in 2018 and has nearly 20 years of HR experience. Prior to his role as Interim Chief People Officer, Schumacher served as Senior Vice President of Human Resources, where he led HR for the Dollar Tree and Family Dollar banners, inclusive of corporate functions, Field, Supply Chain, HR Compliance, Labor Relations, and People Solutions. Jocelyn Konrad named Chief of Dollar Tree Stores and Enterprise Store Operations; Jason Nordin named President of Family Dollar Stores. Jocelyn "Jocy" Konrad has been appointed Chief of Dollar Tree Stores and Enterprise Store Operations, with oversight of all Dollar Tree stores and enterprise store operations services. Jason Nordin has been named President of Family Dollar Stores to play a key leadership role in the banner's formal review of strategic alternatives. Both Konrad and Nordin joined the organization in Sept. 2023."

16:17 EST Helmerich & Payne sees Q1 North America Solutions direct margins $260M-$280M - Sees Q1 International Solutions direct margins ($2M)-$2M. Sees Q1 Gulf of Mexico direct margins $7M-$9M.

16:13 EST Kulicke & Soffa raises quarterly dividend, expands share repurchase program - Kulicke and Soffa Industries announced that its Board of Directors has declared and authorized a quarterly dividend of 20.5c per share of common stock, representing a $0.005 increase over its most recent dividend. This dividend raise highlights the company's commitment to a consistent shareholder return strategy and will be included in the January 7, 2025 dividend payable to holders of record as of the close of business on December 19, 2024. In addition to the quarterly dividend increase, K&S expanded its shareholder return activities with a new $300M share repurchase program authorized by its Board of Directors. This new program will begin after the completion of the company's existing $800M share repurchase program. At the completion of the 2024 fiscal year, the existing repurchase program - originally announced on August 15, 2017 - had $30.3M of authorization remaining and is expected to be completed during the Company's fiscal first quarter 2025, ending December 28, 2024.

16:11 EST Structure Therapeutics doses first patients in ACCESS clinical study - Structure Therapeutics announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS clinical study evaluating GSBR-1290 in participants living with obesity, or overweight with a weight-related comorbidity. GSBR-1290 is an orally-available, nonpeptide small molecule glucagon-like-peptide-1 receptor agonist that has demonstrated competitive weight loss and generally favorable safety and tolerability results in previous studies with once-daily dosing.

16:08 EST Verizon, Knightscope team to power connectivity for advanced public safety tech - Verizon Business announced a partnership with Knightscope," a leading developer of autonomous security robots ASRs , to provide secure, reliable connectivity for the deployment of Knightscope's K5 security robots and K1 emergency communication devices to help elevate safety at commercial and government facilities. This collaboration marks a significant advancement in autonomous security technology, with the K5, powered by the Verizon network, now holding a Federal Risk and Authorization Management Program FedRAMP Moderate Authority to Operate ATO designation from the U.S. Department of Veterans Affairs, a key endorsement of the K5's security compliance." said the company. "Verizon is committed to enhancing public safety by providing seamless and secure connectivity to the latest in autonomous security technology," said Tom Long, an associate director for Verizon's federal business. "Our partnership with Knightscope is a testament to the importance of secure, reliable connectivity in helping safeguard public spaces, and we look forward to further elevating these capabilities through 5G integration."

16:04 EST CVD Equipment receives $3.5M follow on CVI system order - CVD Equipment Corporation announced that it has received a follow on order for a production Chemical Vapor Infiltration system valued at approximately $3.5M. The system is intended to be used to produce advanced, energy efficient materials for use within gas turbine engines. "We are pleased to see that the aerospace industry continues to recover from the impact to air travel caused by the global COVID pandemic. Growth is now projected over the next decade for the aerospace and defense market. We have added to our product line in 2024 with the addition of a CVI system for CMCs, a second-generation silicon bond coat system and an advanced ceramic matrix system in addition to our legacy tow coat system for CMCs. We remain dedicated to support our customer's production scale up as well as their research and development efforts. This order expands our installed base of standard CVI production systems," said Emmanuel Lakios, President and CEO of CVD Equipment Corporation.

15:49 EST North American rail traffic down 0.8% for the week ending November 9 - The Association of American Railroads or AAR reported U.S. rail traffic for the week ending November 9 . For this week, total U.S. weekly rail traffic was 519,115 carloads and intermodal units, up 4.5% compared with the same week last year.Total carloads for the week ending November 9 were 224,722 carloads, down 3.7% compared with the same week in 2023, while U.S. weekly intermodal volume was 294,393 containers and trailers, up 11.7% compared to 2023. Six of the 10 carload commodity groups posted an increase compared with the same week in 2023. They included farm products excl. grain, and food, up 1,659 carloads, to 18,452; chemicals, up 1,257 carloads, to 31,935; and petroleum and petroleum products, up 978 carloads, to 11,084. Commodity groups that posted decreases compared with the same week in 2023 included coal, down 9,941 carloads, to 58,809; nonmetallic minerals, down 2,114 carloads, to 29,186; and motor vehicles and parts, down 1,267 carloads, to 15,276. North American rail volume for the week ending November 9 on 9 reporting U.S., Canadian and Mexican railroads totaled 333,683 carloads, down 3% compared with the same week last year, and 349,527 intermodal units, up 1.5% compared with last year. Total combined weekly rail traffic in North America was 683,210 carloads and intermodal units, down 0.8%. North American rail volume for the first 45 weeks of 2024 was 30,178,530 carloads and intermodal units, up 2.3% compared with 2023. Publicly traded companies in the space include CN (CNI), CSX (CSX), Canadian Pacific Kansas City (CP), Norfolk Southern (NSC), Union Pacific (UNP), (TRN), Greenbrier (GBX), FreightCar America (RAIL), L.B. Foster (FSTR), Wabtec (WAB), GATX (GATX) and Rail Vision (RVSN). Reference Link

15:24 EST CDC says 104 infected with E. coli linked to McDonald's onions as of Nov. 13 - In an update on its investigation of fresh, slivered onions served at McDonald's that were the likely source of an outbreak of E. coli infections, the CDC stated: "As of November 13, a total of 104 people infected with the outbreak strain of E. coli O157:H7 have been reported from 14 states. Illnesses started on dates ranging from September 12, 2024, to October 21, 2024. Of 98 people with information available, 34 have been hospitalized, and 4 people developed hemolytic uremic syndrome, a serious condition that can cause kidney failure. One death has been reported from an older adult in Colorado. This person is not one of those who developed HUS." Reference Link

13:57 EST Occidental says evaluating multiple 2035 activities - Says evaluating considering the recent commodity price volatility. Says Permian, Midland Basin teams "excelled," surpassing production guidance.

13:39 EST Zeta Global falls 10% to $25.50 after Culper Research short report

13:05 EST Booz Allen Ventures invests in Starfish Space - Booz Allen Hamilton announced that its corporate venture capital arm, Booz Allen Ventures has made a strategic investment in Starfish Space, an emerging leader in satellite servicing, inclusive of satellite life extension and end-of-life disposal. This investment aims to strengthen the resilience and sustainability of space infrastructure through innovative offerings for both government and commercial mission sets. This is the third space-focused investment by Booz Allen Ventures and reflects the growing criticality and varied mission needs of the space domain. Founded by former engineers from Blue Origin and NASA, Starfish Space specializes in on-orbit satellite servicing with a focus on satellite life extension and end-of-life disposal. The company's first-of-its-kind autonomous satellite servicing vehicle, Otter, can provide scalable and customizable options for managing satellites and maintaining critical infrastructure, ensuring viability in increasingly congested orbital paths. Most recently, Starfish Space executed its Otter Pup demonstration mission, secured a $37.5 million Strategic Funding Increase contract with the U.S. Space Force, signed a contract with Intelsat for a life extension mission, and partnered with NASA for a debris inspection mission in low Earth orbit.

12:55 EST PG&E up 1% to $21.40 after California's Atomic Canyon announces deal

12:45 EST Steel Dynamics exec Alvarez sells 6,650 common shares - In a regulatory filing, Steel Dynamics senior vice president Miguel Alvarez disclosed the sale of 6,650 common shares of the company on November 13 at a price of $143 per share.

12:08 EST Pure Storage announces strategic investment in CoreWeave - Pure Storage announced Pure Storage's strategic investment in CoreWeave to accelerate AI cloud services innovation. Alongside the investment, the companies unveiled a strategic partnership, enabling customers to leverage the Pure Storage platform within CoreWeave Cloud. The Pure Storage platform is now available as an option within CoreWeave's dedicated environments, which customers access through the CoreWeave Platform, a no compromise engineering solution purpose-built for some of the world's most compute intensive workloads. The CoreWeave Platform uses automation to simplify complexity, maximizing infrastructure performance and efficiency, while Pure Storage offers a highly scalable, efficient storage solution, with joint solutions already deployed in production at supercomputing scale across thousands of GPUs. Together, they empower customers to accelerate their time to market

12:01 EST Paymentus rises 35.6% - Paymentus is up 35.6%, or $9.47 to $36.08.

12:00 EST Eastman Kodak falls -16.3% - Eastman Kodak is down -16.3%, or -90c to $4.61.

12:00 EST Paysafe falls -25.0% - Paysafe is down -25.0%, or -$6.37 to $19.11.

11:48 EST VF Corp. credit rating cut to junk by S&P Global - S&P Global Ratings lowered VF Corp.'s issuer credit rating from investment-grade to "BB" from "BBB-" and short-term and commercial paper ratings to "B" from "A-3". VF Corp.'s fiscal Q2's "weak earnings indicate that its portfolio of brands remains challenged and are still declining," S&P said in a statement. It revised its forecast to reflect expectations for lower demand and the sale of Supreme. As a result, S&P estimates the company's leverage will remain well above 4.5-to,es in fiscal 2025. The downgrade reflects a less favorable view of VF's competitive position due to ongoing revenue declines in its top four brands and weaker credit ratios, the agency said.

11:36 EST Stellantis appoints Davide Grasso as chief heritage officer - Stellantis announced the appointment of Davide Grasso as Stellantis Chief Heritage Officer reporting to Carlos Tavares, CEO. In this newly created position, he will be responsible for the curation of the history and patrimony of the 14 brands of Stellantis. Creating a bridge between their rich histories and their future directions, this global role will build awareness and connections with customers, brands, communities and the various institutions present in the territories where we operate. The role will be responsible for the partnering with our heritage centers, museums and archives while collaborating with the Brand CEOs on future business opportunities and to foster and further grow the rich and passionate history of the individual brands of Stellantis.

11:11 EST QMMM Holdings Ltd trading resumes

11:03 EST City of Los Angeles selects Clariti, Unisys for permitting system - Clariti, in partnership with Unisys, announced that the Los Angeles Department of Building and Safety has selected Clariti's enterprise community development software to replace its current system. The system is designed to improve the customer experience, reduce department costs, and streamline processes to save staff time. It will consolidate all LADBS development services departments into one unified platform, making it easier for customers, small businesses, and contractors to interact with the city for all permitting activities.

10:54 EST Galaxy Payroll Group Ltd trading halted, volatility trading pause

10:36 EST comScore trading resumes

10:17 EST Frontier stockholders approve acquisition by Verizon - Frontier Communications Parent (FYBR) announced that its stockholders approved the acquisition by Verizon Communications (VZ) at its special meeting held on November 13, 2024. Approximately 63% of stockholders voted "For" the merger agreement proposal, with ten of the company's top 12 stockholders voting to approve the transaction. On September 5, 2024, Frontier and Verizon announced they had entered into a merger agreement, pursuant to which Verizon would acquire Frontier in an all-cash transaction. Frontier stockholders will receive $38.50 per share in cash, representing a premium of 37% to Frontier's unaffected share price on September 3, 2024. The transaction is expected to close by the first quarter of 2026, subject to receipt of certain regulatory approvals and other customary closing conditions.

10:02 EST Lionsgate, Kingdom Story Company renew three-year first-look deal - Lionsgate Studios and Kingdom Story Company announced that the companies have agreed to renew their three-year first-look deal, extending the studios' total collaboration to ten years. "Over the past decade, Kingdom films have established a unique ability to connect with their audiences in the faith community and beyond through high quality storytelling and exceptional productions, like their holiday hit The Best Christmas Pageant Ever. We're proud to continue to collaborate with Kevin, Andy, Brandon and the entire team and thrilled that we are their creative home," said Lionsgate Motion Picture Group Chair Adam Fogelson.

10:00 EST Spire Global rises 19.7% - Spire Global is up 19.7%, or $2.32 to $14.11.

10:00 EST Danimer Scientific falls -10.7% - Danimer Scientific is down -10.7%, or -$1.07 to $8.93.

10:00 EST Paysafe falls -22.5% - Paysafe is down -22.5%, or -$5.73 to $19.74.

09:56 EST Spirit Airlines says noteholder deal, if reached, would cancel equity - Spirit Airlines said last night that its unable to file its quarterly report for the quarter ended September 30 "by the prescribed due date without unreasonable effort or expense." As previously disclosed, Spirit has been in discussions with holders of its senior secured notes due 2025 and convertible senior notes due 2026 with respect to restructuring the obligations owed by the company to the noteholders, as well as exploring strategic alternatives and other ways to improve liquidity. "The negotiations, with a supermajority of the Noteholders, have remained productive, have advanced materially and are continuing in the near term, but have also diverted significant management time and internal resources from the Company's processes for reviewing and completing its financial statements and related disclosures," Spirit said in a statement. If a definitive agreement with such noteholders is reached, it is expected to lead to the cancellation of the company's existing equity, Spirit Airlines added. Shares of Spirit Airlines are down 57% to $1.37 in early trading.

09:50 EST Pulmatrix trading resumes

09:49 EST Altus Power rises 22.5% - Altus Power is up 22.5%, or 70c to $3.81.

09:48 EST Loar Holdings falls -7.8% - Loar Holdings is down -7.8%, or -$6.83 to $81.28.

09:47 EST Rocket Companies falls -8.4% - Rocket Companies is down -8.4%, or -$1.30 to $14.23.

09:47 EST Paysafe falls -18.8% - Paysafe is down -18.8%, or -$4.79 to $20.68.

09:42 EST Danimer Scientific trading resumes

09:36 EST Danimer Scientific trading halted, volatility trading pause

09:35 EST BTC Digital Ltd trading resumes

09:30 EST Inseego trading halted, volatility trading pause

09:23 EST Lexaria Bioscience receives HREC approval for Phase 1b DehydraTECH GLP-1 study - Lexaria Bioscience has received lead clinical site human research ethics committee approval that was required before dosing can begin in the Company's Phase 1b, 12-week chronic study GLP-1-H24-4. The Company is also announcing that clinical test article manufacturing for all planned Study arms has already been completed. This includes production for the four planned DehydraTECH formulation Study arms and clinical repackaging of the commercially available Rybelsus comparator tablets for the Study control arm as follows: Arm 1 - DehydraTECH-CBD capsules; Arm 2 - DehydraTECH-semaglutide capsules; Arm 3 - DehydraTECH-semaglutide combined with DehydraTECH-CBD capsules; Arm 4 - Rybelsus tablets; Arm 5 - DehydraTECH-tirzepatide capsules. It is possible that the First Patient, First Dose Study milestone could be achieved in late December, and failing that, in January, 2025. The Study is planned to be conducted using seven clinical investigational sites in Australia as a registrational Phase 1b study within Australian clinical regulatory authority regulations. HREC approval has been received for the primary clinical site, while clinical trial notification acknowledgement by the Australian Therapeutic Goods Administration and HREC approvals for the remaining clinical sites remain to be completed; but expected shortly now that primary site HREC approval is in hand. Quality control release testing of the clinical test articles also remains to be completed. The Study, upon completion, is expected to be equally regarded as a Phase 1b registrational study by the U.S. Food and Drug Administration.

09:12 EST Carvana expands same day delivery to Las Vegas - Carvana announced the expansion of its same day vehicle delivery offering to the greater Las Vegas, Nevada area. Select Las Vegas area residents can now take delivery of a vehicle purchase as soon as the same day they place an order on Carvana.com.

09:09 EST Tonix Pharmaceuticals announces publication of study on tolerability of TNX-801 - Tonix Pharmaceuticals announced the publication of a paper entitled, "Recombinant Chimeric Horsepox Virus, TNX-801, is Attenuated Relative to Vaccinia Virus Strains in Both In Vitro and In Vivo Models," in the peer-reviewed journal mSphere. The publication presents data demonstrating that TNX-801 is less virulent than 20th Century vaccinia vaccines in immune-compromised mice. Previously, single-dose vaccination with TNX-801 was shown to protect animals from a lethal challenge with Clade Ia monkeypox. Combined with the ability of TNX-801 to protect animals against lethal challenge with Clade Ia monkeypox virus, the Company believes that the new tolerability data support the idea that TNX-801 is a candidate vaccine to control the ongoing PHEICs with mpox Clade Ib and mpox Clade IIb.

09:07 EST Instacart and Geissler's Supermarkets announce rollout of Caper Carts - Geissler's Supermarkets, a seven-store Independent Grocers Alliance retailer with locations in Connecticut and Massachusetts, and Instacart announced the rollout of Caper Carts, Instacart's AI-powered smart carts, to all seven Geissler's locations across Connecticut and Massachusetts. Geissler's is the first grocer to replace a majority of their traditional shopping carts with Caper Carts at all locations. Geissler's first partnered with Instacart in 2023 to launch same-day delivery, and with the introduction of Caper Carts, they are the first retailer in Massachusetts and Connecticut to launch with the kind of technology offered by Caper Carts.

09:06 EST ServiceNow advances autonomous AI on the Now Platform - ServiceNow announced new generative AI GenAI and governance innovations to advance autonomous, responsible AI on the Now Platform. With this launch, ServiceNow is adding more than 150 GenAI innovations to its portfolio for customers. This includes new, expanded Now Assist capabilities that drive greater visibility and controls with an AI Governance offering for secure and compliant AI practices. Native multilingual support in Now Assist extends GenAI's global footprint for seamless, culturally aware communications and translations. Finally, purpose-built solutions deliver new Now Assist use cases for configuration management, contract management, legal services, and health and safety. As enterprises have accelerated the adoption of GenAI, they are discovering that siloed applications and scattered data are barriers to impact and that establishing clearly defined, human-centric governance processes are essential to the effective use and oversight of GenAI. That's why ServiceNow delivers a winning combination of one platform with an integrated data layer and continues to optimize its AI platform for speed, scale, and security. The single architecture of the Now Platform helps ensure strong governance is embedded in its Now Assist GenAI solutions, models, and agents no matter where they are deployed in an organization.

09:06 EST Invizyne begins trading on Nasdaq - Invizyne Technologies announced that its common shares will begin trading on the NASDAQ today, November 13, 2024 at approximately 12:00pm EST under the ticker symbol "IZTC."

09:05 EST Liberty Broadband trading resumes

09:04 EST La Rosa Holdings acquires 100% ownership of La Rosa Realty Premier franchisee - La Rosa announced the acquisition of the remaining 49% interest in its franchisee, La Rosa Realty Premier located in Orlando, Florida. This acquisition follows the Company's initial purchase of 51% interest in December 2023, bringing La Rosa's total ownership of Realty Premier to 100%.

09:03 EST LiqTech awarded order from leading technology company - LiqTech International announced the receipt of an order from a leading technology company for lithium brine production in the U.S. Electric vehicles are powered by batteries that rely on lithium, an indispensable metal that uniquely enables a wide variety of electrode chemistries with high volumetric energy density and fast charging. The broad adoption of electric vehicles requires a substantial increase in lithium production. To realize this electric future, traditional methods of lithium production must be replaced with new technology that can deliver higher rates of production while meeting basic environmental standards. Brine resources hold a substantial amount of the world's lithium, but until now, the lack of a scalable extraction technology has hindered their development. One of the suitable solutions for lithium brine extraction is ion exchange. LiqTech ultrafiltration membrane filtration technology shows the huge potential to be an excellent pre-treatment step for enhancing downstream ion exchange process. The new commercial system is scheduled to be delivered to the customer in the Q4.

09:01 EST Pulmatrix announces merger agreement with Cullgen - Pulmatrix announced a merger agreement with Cullgen, a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE platform to discover and advance therapeutics for the treatment of cancer and other diseases. Cullgen utilizes its proprietary technology platform, uSMITE, featuring novel E3 ligands, to build the next generation of targeted protein degraders and degrader-antibody conjugates. Subject to the terms and conditions of the merger agreement, and upon the closing of the merger, pre-merger Pulmatrix stockholders are expected to own approximately 3.6% of the combined company, and pre-merger Cullgen stockholders are expected to own approximately 96.4% of the combined company which will operate under the name Cullgen Inc., be headquartered in San Diego, CA and trade on The Nasdaq Capital Market. Pulmatrix stockholders will also receive a special cash dividend to the extent that Pulmatrix's net cash at closing exceeds $2.5M, subject to certain adjustments. The transaction is expected to close by the end of March 2025, subject to obtaining stockholder and CSRC approval.

09:00 EST Liberty Broadband trading resumes

08:56 EST Montana Technologies Corp. changes name to AirJoule Technologies - Montana Technologies has changed its corporate name to AirJoule Technologies Corporation. The Company's common stock and warrants will continue to trade on the Nasdaq Capital Market under the ticker symbols "AIRJ" and "AIRJW", respectively; no action is required by existing stockholders. The AirJoule Technologies name better reflects the Company's position as the developer of AirJoule. The change also aligns the corporate name with AirJoule, the Company's 50/50 joint venture with GE Vernova to advance and commercialize atmospheric water harvesting products featuring AirJoule technology.

08:50 EST Tharimmune granted patent for delivery of molecularly targeted therapeutics - Tharimmune announced that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric nanoparticles created for carrying therapeutic and targeting agents. With particular utility in cancer therapies, this innovative platform is designed to enhance the delivery of therapeutic antibodies and peptides, which are often limited by enzymatic degradation and poor systemic circulation. The patent covers the design, preparation and therapeutic application of nanoparticles formed from biodegradable block copolymers. These nanoparticles exhibit tunable size, non-toxic profiles and the ability to prolong drug half-life in the bloodstream. By penetrating biological barriers and delivering encapsulated drug directly to disease sites, reduces systemic side effects and toxicity while improving the therapy's effectiveness. An application for a comparable U.S. patent has been submitted to the United States Patent and Trademark Office, and is currently under review. This new patent complements Tharimmune's existing pipeline, including colonic targeting developed through the Company's partnership with Intract Pharma. While Tharimmune initially focused on tablet-based solutions for lower gastrointestinal delivery, this new intellectual property represents a potential platform to complement its growing pipeline. Tharimmune is also actively exploring strategic partnerships with companies that specialize in antibody conjugation to further enhance the targeting capabilities of its platform.

08:47 EST Sky Quarry announces launch of European Financing Effort - Sky Quarry announced the launch of its European Financing Effort. This expansion aims to leverage growth capital in the European market. The Company is making this announcement following numerous meetings with institutional investors across several European countries.

08:45 EST FDA grants Simulations Plus to use PBPK to expand mechanistic modeling for LAI - Simulations Plus announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration FDA to use physiologically based pharmacokinetic PBPK approaches in GastroPlus to build and validate mechanistic in vitro-in vivo correlations IVIVCs for long-acting injectable LAI technologies through a joint proposal with the University of Connecticut's School of Pharmacy, Department of Pharmaceutical Sciences. This project aims to use the GastroPlus PBPK platform to investigate the intricate relationship between LAI formulation critical quality attributes CQAs and physiological factors at the injection site to accurately predict in vivo drug release and absorption. Dr. Diane Burgess, Board of Trustees Distinguished Professor of Pharmaceutics and Pfizer Distinguished Endowed Chair of Pharmaceutical Technology at the University of Connecticut and her lab will generate in vitro and in vivo data for marketed LAI suspension products using novel discriminatory systems. The scientific team at Simulations Plus will use this data, along with additional inputs from research collaborators, to develop PBPK models and apply them to validate mechanistic IVIVCs. This effort is expected to lay the groundwork for a practical alternative to in vivo studies in establishing bioequivalence BE for additional LAI product technologies.

08:44 EST Locafy secures media contract with value of up to $6.5M - Locafy has partnered with one of the largest media and information services companies worldwide. The collaboration will address critical SEO challenges impacting the partner's widely read news website and specialized content platforms, aiming to restore revenue from sponsored content, enhance advertiser visibility, and shield content against recent and potential future SEO penalties resulting from search engine algorithm changes. Following recent SEO policy updates, including Google's new enforcement actions related to site reputation and search ranking penalties, many publishers have faced the removal of sponsored content from their platforms, impacting both revenue and formerly valuable product offerings. Locafy's proprietary Article Accelerator solutions offer an effective response to this industry-wide challenge, enabling publishers to safely reintegrate valuable content while minimizing SEO performance risk. Pursuant to the agreement, Locafy will implement sponsored articles representing approximately US$500,000 in potential annualized recurring revenue during the initial phase. These initial articles are approximately 8% of the total articles removed from the partner's platforms and just one of the high value niche categories they previously monetized using their own publishing assets. Locafy's publishing solutions enable the media company to leverage its sizable client base to offer national SEO solutions while shielding their masthead brands entirely from any potential search engine penalties.

08:42 EST Liberty Media CEO Greg Maffei to step down - Liberty Media announced that president and CEO, Greg Maffei, will be stepping down from his role at the end of 2024. Liberty Media's chairman, John Malone, will assume the role of interim CEO and will work closely with the Liberty Media executive team and the board of directors to ensure a transition. Maffei will step down at the expiration of his contract at year-end and will serve as a senior advisor effective January 1 to support the management transition.

08:41 EST Liberty Media announces plan to split off Liberty Live Group - Liberty Media announced that it is pursuing a plan to split off the Liberty Live Group. Immediately prior to effecting the split-off, Liberty Media's subsidiary Quint would be reattributed from the Formula One Group to the Liberty Live Group in exchange for certain private assets. Any cash consideration would be determined at a future date based on relative valuations at the time of the reattribution. Liberty Media will effect the split-off through the redemption of Liberty Media's Liberty Live common stock in exchange for common stock of a newly formed company to be called Liberty Live, Inc. Liberty Media would redeem each outstanding share of its Series A, Series B and Series C Liberty Live common stock for one share of the corresponding series of common stock of Liberty Live, Inc. As a result of the split-off, Liberty Media and Liberty Live would be separate publicly traded companies, and Liberty Media would no longer have a tracking stock structure. Liberty Live will hold approximately 69.6M shares of Live Nation (LYV), Quint, certain private assets currently attributed to Liberty Live Group, corporate cash and debt obligations attributed to the Liberty Live Group, together with other assets as may be determined by Liberty Media prior to the split-off. Liberty Media will hold its subsidiaries Formula 1 and MotoGP, certain private assets currently attributed to Formula One Group, corporate cash and debt obligations attributed to the Formula One Group, together with other assets as may be determined by Liberty Media prior to the split-off. Liberty Media is expected to continue to trade on Nasdaq. Liberty Live common stock is expected to trade on Nasdaq or, if necessary, to be quoted on the OTC Markets. Additional information will be available at a later date. The split-off is subject to various conditions including, among other things, certain requisite approvals of holders of Series A and Series B Liberty Live common stock and the receipt of an opinion of tax counsel. The split-off is intended to be tax-free to stockholders of Liberty Media. Subject to the satisfaction of the conditions, Liberty Media expects to complete the split-off in the second half of 2025.

08:40 EST iPower renews credit facility with JPMorgan Chase - iPower announced the renewal of its secured revolving credit facility with JPMorgan Chase, extending the maturity by three years to November 2027.The new facility has a revolving commitment of $15.0 million, with an accordion feature to obtain additional lender commitments to increase the facility size up to $40.0 million in the aggregate. Under the new agreement, the interest on borrowings will be based on SOFR plus 2.25% - 2.50%.

08:39 EST Ideal Power renews credit facility with JPMorgan Chase - iPower announced the renewal of its secured revolving credit facility with JPMorgan Chase, extending the maturity by three years to November 2027.The new facility has a revolving commitment of $15.0 million, with an accordion feature to obtain additional lender commitments to increase the facility size up to $40.0 million in the aggregate. Under the new agreement, the interest on borrowings will be based on SOFR plus 2.25% - 2.50%.

08:38 EST Intelligent Bio Solutions announces 'strong initial results' from PK study - Intelligent Bio Solutions announced strong initial results from its Pharmacokinetic, PK, study required for an FDA 510(k) submission. The data from the PK study shows that fingerprint sweat mimics the rate and extent of codeine in blood and saliva. The study successfully demonstrated that fingerprint sweat provides a reliable sample matrix for drug detection, showing quantitative PK data closely aligned to blood, based on statistical comparisons made at the 95% confidence level. FDA 510(k) clearance would enable INBS to introduce its innovative drug screening technology to the US market in 2025. The PK study results and other clinical data from the Company's clinical study plan will be submitted as part of the Company's 510(k) submission, expected in the fourth calendar quarter of this year. INBS is well-positioned to meet the increasing demand for drug testing in the United States, particularly in safety-critical industries like construction, mining, and transportation, as well as in law enforcement, drug rehabilitation, and forensic sectors.

08:36 EST Safety Shot announces key highlights from Q3 - Safety Shot announced key highlights and accomplishments from the third quarter of 2024, demonstrating significant strides in brand development, strategic partnerships, and market expansion. In the last several months, the Company has achieved significant milestones, including: Rebranding and Product Innovation: Officially rebranded from Safety Shot to Sure Shot, introducing a bold new visual identity and convenient product formats, including 4oz bottles and on-the-go stick packs. Improved the product's taste profile based on consumer feedback, further enhancing its appeal and driving customer satisfaction. Strategic Partnerships and Distribution Expansion: Secured a major distribution partnership with 7-Eleven, launching its 4oz bottles in over 300 stores across the Chicago area. Formed a strategic alliance with Stellar Partners to expand into the travel retail market, making Sure Shot available in airports across the United States. Formed strategic alliances with Launchpad's Network All Roads Travel to target the college student demographic and Stellar Partners to expand into the travel retail market. Continued to expand its on-premises presence through agreements with bars and restaurants, making the product readily available in social settings. Expanded distribution network through a strategic partnership with Atlantic Beverage Distributors, increasing Sure Shot's presence in Massachusetts and Rhode Island. Strengthening the Foundation: Granted a new patent for its innovative BAC-reducing formulation, reinforcing its commitment to scientific validation and intellectual property protection. President of the Company, Jordan Schur, invested an additional $3.4 million, demonstrating confidence in the company's future. Positive clinical study results further validated the product's efficacy and potential benefits. A new e-commerce partnership with VENDO was formed to boost online sales and brand visibility. Sharpening Focus: Announced plans to spin-off its wellness consumer products segment, Caring Brands, into a separate, publicly traded company. This strategic move will allow Safety Shot to focus exclusively on its flagship product and its growth potential in the functional beverage market. The spin-off is expected to be completed within 90 days. As part of the spin-off, Safety Shot shareholders will receive a dividend of two million shares of Caring Brands stock. This provides shareholders with direct ownership in a new company poised for growth in the consumer wellness market. "Q3 2024 has been a period of tremendous growth and transformation for Safety Shot," said Jarrett Boon, CEO of Safety Shot. "The rebranding of 'Sure Shot,' along with the introduction of our new 4oz bottles and convenient stick packs, has revitalized our product line and strengthened our connection with consumers. These strategic initiatives, combined with our expanded distribution network and key partnerships, are driving strong performance and positioning us to deliver exceptional value to our shareholders. We look forward to continued growth with our Sure Shot brand and plan to announce more news in the near future highlighting Safety Shot's success."

08:34 EST Fathom announces strategic leadership apppointments - Fathom Holdings has announced strategic leadership appointments. Jon Gwin, previously COO, has been named to the newly created position of Chief Revenue Officer. Additionally, Samantha Giuggio, formerly COO of Fathom Realty, has been promoted to President of Fathom Realty and COO of Fathom Holdings. In his new role, Gwin will focus on revenue generation, strategic partnerships, and expansion initiatives across Fathom's real estate, mortgage, and title divisions, drawing on nearly a decade of industry experience. As COO, he played a key role in advancing growth and operational success throughout Fathom's diverse portfolio of brands. Samantha Giuggio Named President of Fathom Realty and COO of Fathom Holdings. Giuggio, previously COO of Fathom Realty, will expand her leadership responsibilities as President of Fathom Realty and COO of Fathom Holdings. Known for her expertise in leadership and agent productivity, Giuggio brings over 14 years of experience with Fathom, where she has been instrumental in cultivating high-performance teams and a collaborative company culture. These leadership advancements highlight Fathom's commitment to scaling its operations and optimizing growth through innovative strategies.

08:31 EST Charter to acquire Liberty Broadband in all-stock transaction

08:30 EST ABB selected by OHB System to develop, build thermal infrared payloads - ABB has been selected by the German space and technology company OHB System AG to develop and build the thermal infrared payloads for the European Space Agency's, ESA, Earth Explorer Harmony satellites, planned to launch in 2029. ABB will equip the two satellites with multispectral thermal infrared payloads capable of measuring a wide range of environmental parameters, including sea surface temperature and the position of clouds and their motion. Financial details were not disclosed.

08:28 EST SAG Holdings completes implementation of automation technology at center - SAG Holdings announced that Filtec Private Limited, a wholly-owned subsidiary of SAG Holdings, has completed implementation of automation technology in its distribution center, embracing industrial innovation and leveraging advanced robotics and digital solutions to redefine its operations.

08:26 EST DLH Holdings reduces debt, amends credit facility - DLH Holdings announced selected key metrics for the fiscal year ended September 30, 2024 and an amendment to its syndicated credit agreement. Total debt at fiscal year-end was $154.6 million compared to $179.4 million as of September 30, 2023, reflecting a total reduction of $24.8 million during fiscal 2024 - including $11.9 million in the fourth quarter. As a result of the Company's focus on eliminating debt through voluntary prepayments, all mandatory amortization payments for fiscal 2025 have been satisfied. DLH has engaged with its lenders to negotiate an amendment to its credit agreement that modifies the financial covenants - specifically the Total Leverage Ratio and Fixed Charge Coverage Ratio - and borrowing capacity of the Company's revolving loan. The modification of the financial covenants increases the maximum threshold on the Total Leverage Ratio and reduces the minimum threshold on the Fixed Charge Coverage Ratio for future quarters. In addition, the amendment aligns the revolver's borrowing capacity with operational needs by reducing the maximum from $70 million to $50 million. There were no modifications to the maturity or pricing terms of the credit facility. The joint lead arrangers led the amendment efforts along with the DLH Board of Directors and executive management. Management believes the amendment offers the Company flexibility to navigate the anticipated transition of a portion of its business base to set-aside, small business contractors, primarily the Department of Veterans Affairs' Consolidated Mail Outpatient Pharmacy program.

08:25 EST Liberty Broadband trading halted, news pending

08:23 EST CervoMed appoints Ordonez, Rosch as SVPs - CervoMed reported two senior leadership appointments to advance continued development of neflamapimod. Claudia Ordonez, MD, joined CervoMed as Senior Vice President, SVP, Medical Science in October 2024. Additionally, Mark De Rosch, Ph.D., FRAPS, recently joined CervoMed as Senior Vice President, Regulatory and Government Affairs and Program Management.

08:22 EST Evaxion Biotech receives, appeals delisting determination from Nasdaq - Evaxion Biotech received a letter dated November 11, 2024, with a delisting determination from Nasdaq Stock Market for failure to maintain stockholders' equity of at least $2.5 million as required by Nasdaq Listing Rule 5550(b)(1). Evaxion has already appealed the determination by requesting a hearing on the matter and will seek another 180-day extension to comply with Nasdaq's equity requirement. The appeal will stay any trading suspension of our American Depositary Shares until completion of the Nasdaq hearing process and expiration of any additional extension period granted by the panel following the hearing. During any additional extension, Evaxion intends to regain compliance and maintain its Nasdaq listing, however no guarantee of such compliance can be given.

08:22 EST Yoshitsu launches new online sales platform for Reiwatakiya brand in U.K. - Tokyo Lifestyle announced the launch of a new online sales platform for its Reiwatakiya brand in the UK. The platform will serve as a one-stop online hub for European customers to conveniently purchase Japanese health, beauty, and lifestyle products, with local shipping options available across Europe. This launch marks a significant milestone in the Company's ongoing regional expansion strategy.

08:20 EST Dayforce announces Dayforce AI Agents - Dayforce announced Dayforce AI Agents, the next evolution of AI innovation designed to unlock creativity, productivity, and efficiency for employees by helping automate tedious and time-consuming day-to-day tasks. With a single source of trustworthy people data at its core, Dayforce AI Agents are built to fuel job satisfaction and performance, while accelerating workflows across the employee lifecycle.

08:19 EST Dayforce announces Dayforce Communications - Dayforce introduced Dayforce Communications, a new way for organizations to optimize communications throughout the entire employee lifecycle. Dayforce Communications will provide HR teams with a unified way to communicate with past, present, and future talent across any channel - all within the Dayforce platform.

08:18 EST Oklo secures partnerships for up to 750 MW of power for U.S. data centers - Oklo has received letters of intent, or LOIs, and is partnering with two major data center providers to deliver up to 750 megawatts, or MW, of low carbon power for data centers across the U.S. These commitments expand Oklo's customer pipeline to approximately 2,100 MW, underscoring the demand for Oklo's dedicated clean energy solutions. Under these LOIs, Oklo will work with one of the fastest-growing data center companies to deploy its powerhouses in select markets. This collaboration supports Oklo's expanding footprint, including its announced sites in Idaho, Ohio, Texas, and Wyoming, reinforcing the company's commitment to advancing clean, resilient power options nationwide. Oklo's Aurora powerhouse design provides power directly on-site or nearby, with flexible 15 MW and 50 MW units that can be deployed in phases.

08:17 EST Organovo to present data of FXR314 in Phase 2 MASH study - Organovo announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases, AASLD. The presentation, by Dr. Eric Lawitz of the Texas Liver Institute, will describe the findings from the FXR314 Phase 2 MASH study. The meeting will be held November 15-19, 2024 in San Diego, California.

08:16 EST AgriFORCE Growing Systems provides update on strategic shift - AgriFORCE Growing Systems provides an update to shareholders highlighting the Company's ongoing strategic shift toward advancement of its sustainable technology initiatives and its signing of a Letter of Intent, LOI, to purchase a Bitcoin mining facility in Alberta, Canada, powered by sustainable energy. AgriFORCE CEO Jolie Kahn stated, "Our strategic vision remains centered on the pursuit of sustainable technology opportunities that will support the company's dedication to building long-term shareholder value. To this end, we announce the next phase of our transition, highlighted by the integration of Bitcoin mining solutions and the ancillary environmental and power-generation benefits that result from engaging in that business. We recognize the potential of Bitcoin and other digital currencies in facilitating sustainable financial transactions and intend to utilize 10-20% of our future capital raised to purchase and hold Bitcoin. We look forward to keeping our shareholders informed of our ongoing exploration of additional innovative platforms that align with our dynamic growth strategy.

08:15 EST Volato launches third-party operator program - Volato announced that following the recent integration of flyExclusive, the fifth-largest operator in the United States, Vaunt, launched its third-party operator program. This initiative marks a new chapter for Vaunt, as the platform welcomes other operators to join and benefit from its technology platform and extensive member base. With the integration of flyExclusive, Vaunt has demonstrated its capability to provide operators with a dynamic channel for maximizing the utilization of empty leg flights. Now, other operators can access this same value proposition, benefiting from increased visibility, enhanced operational efficiency, and the opportunity to grow alongside Vaunt.

08:14 EST Demopolis Equity Partners announces strategic partnership with TPG - Demopolis Equity Partners, announced that it has signed a definitive agreement to receive a strategic minority investment from TPG TPG will invest in Demopolis through TPG NEXT, its strategy focused on seeding and scaling the next generation of investment firms by providing growth capital and operational and investment support. "Tim and his team bring a unique combination of professional experiences that position Demopolis as a partner of choice to management teams and founders," said Pamela Pavkov, Managing Partner of TPG NEXT. "Their distinct approach has resulted in strong success previously as an independent sponsor, and we're excited to work together in this next stage of growth to support and scale the Demopolis platform." Through its partnership with TPG, Demopolis will gain access to a suite of strategic and operational capabilities to support the firm's expansion, including areas such as capital formation, capital markets, investment sourcing, and diligence. The transaction is expected to close in the fourth quarter of 2024.

08:11 EST Mobix Lab enters strategic partnership with TalkingHeads Wireless - Mobix Labs announced a strategic partnership with TalkingHeads Wireless. This collaboration will focus on developing products aimed at significantly reducing power consumption in base stations through the integration of advanced AI technologies and power-aware radio architectures.

08:07 EST Ituran's subsidary signs contract with Nissan - Ituran Location and Control (ITRN) announced that following its long-term partnership with Nissan in Mexico, Ituran's subsidiary in Chile has signed a 5-year contract with Nissan (NSANY) Chile. Under this agreement, Ituran will provide the Vehicle Location Unit, or VLU, and a suite of telematics and stolen vehicle recovery, or SVR, services to Nissan and its customers throughout Chile. Following their car purchase, Nissan's customers will enjoy a one year free trial of Ituran's service which will be paid for by Nissan. This agreement will initially cover three vehicle models, with an expected addition of tens of thousands of vehicles over the years. The VLU unit will be pre-installed in these models before reaching the dealers.

08:05 EST ViaSat to launch home and mobile broadband service in Mexico - Viasat announced the launch of its innovative home and mobile broadband service in Mexico. Viasat, in collaboration with Altan, the Mexican telecommunications wholesaler, will integrate Viasat's satellite and wireless LTE technologies with Altan's shared mobile network and provide cellular coverage for consumers in previously uncovered areas across Mexico. Viasat's service is available today in 13 states across Mexico, providing cellular coverage to more than one hundred and fifty thousand individuals, enabling them to take advantage of internet connectivity. Viasat's innovative service seamlessly combines cutting-edge satellite and wireless systems to provide LTE over satellite via a cost-efficient, power-independent, wireless LTE infrastructure. This collaboration aims to expand the availability of high-speed broadband to remote communities throughout Mexico. According to the U.S. Department of Commerce's International Trade Administration, approximately 30% of Mexico's population live in areas without broadband access.

08:05 EST ProPhase Labs anticipates 'significant sequential improvement' in revenue in Q4 - ProPhase anticipates significant sequential improvement in revenues and EBITDA in Q4 2024, and beyond, driven by strategic advancements across its subsidiaries. The company remains financially strong, with $3.1 million in cash and cash equivalents as of November 12, 2024, and an improved working capital position from the quarter end.

07:59 EST Ingredion appoints Mark Karns as VP, corporate development and M&A - Ingredion announced the appointment of Mark Karns as vice president, corporate development and M&A, effective December 2, 2024. Karns will serve as a member of the executive leadership team and will report to Jim Zallie, president and CEO. Karns' role will lead a combined corporate strategy and M&A function to align and optimize Ingredion's strategic growth agenda while driving the execution of M&A projects across the company. Karns joins Ingredion from Whirlpool Corporation, where he served as the global head of mergers and acquisitions, focusing on the development and execution of the company's portfolio transformation strategies.

07:57 EST Idaho Strategic provides rare earth elements update, plans for 2025 season - Idaho Strategic Resources provided an update on its extensive Idaho-based rare earth elements landholdings, including its plans for the 2025 REE exploration field season focusing on the Company's Lemhi Pass project. To recap, on November 15th, 2023 IDR announced results from analysis of sampling at two prospects within its Lemhi Pass project. And as previously stated, the distribution of rare earth elements analyzed was 58% Nd, 8% Pr, 8% Sm, and 2% Dy, with these four elements combined to account for up to 76% of the total rare earth elements percentage. Idaho Strategic's geologists, among others, speculate the favorable mix of REEs may be due to the substitution of lanthanum for a greater concentration of neodymium as illustrated in many Lemhi Pass samples analyzed to date. While much more work is required the Company's initial findings support the potential for favorable project economics moving forward. As part of its ongoing analysis, and ahead of the 2025 work season, the company contracted Alpha Geologic for further study of samples from its Mineral Hill, Diamond Creek and Lemhi Pass projects. In 2025 the Company has plans for a considerably larger trenching and low-impact air rotary drilling program at Lemhi Pass in comparison to past efforts. Spanning over 12,000 acres, the Company's Lemhi Pass project is expansive and exploring it thoroughly will take time. Using a combination of trenching and air rotary drilling is the best and lowest cost method for quick, larger scale exploration to aid in the eventual planning for a core drilling program and future resource definition. Idaho Strategic's President and CEO, John Swallow commented, "We are understandably pleased with the results coming out of our Lemhi Pass project, especially in comparison to other well-known deposits across the globe, and just as domestic sourcing of REEs and mining in Idaho is receiving increased attention. It is also important to note that in concert with planned and ongoing REE exploration, we are also working with multiple national laboratories and independent companies to advance our understanding of the minerology of Idaho's REE projects, and to investigate various separation and processing technologies. Given the specific nature of processing and separating REEs, we felt it necessary to supply REE samples from our projects for the development of innovative processing and separation technologies, which could inevitably result in those solutions/technologies being tailored to the minerology of our projects."

07:53 EST Aclara Resources receives support from U.S. Department of Commerce - Aclara Resources is working with the U.S. Department of Commerce's International Trade Administration, through its SelectUSA program, to conduct a study aimed at identifying the optimal site for Aclara's planned separation facility in the United States. The SelectUSA program fosters business investment that supports economic development and job creation in the United States. To date, SelectUSA has facilitated over $250 billion in investments, creating or retaining more than 230,000 jobs across the country.

07:49 EST Lexeo Therapeutics sees cash runway into 2027 - Cash Position: As of September 30, 2024, cash and cash equivalents were $157.0 million, which Lexeo believes will be sufficient to fund operations into 2027.

07:46 EST Tilray's 10 Barrel Brewing announces 13th Annual Pray for Snow Party - 10 Barrel Brewing, a subsidiary of Tilray Brands, announces the 13th Annual Pray for Snow Party, a free, all-ages event celebrating the festivities of the winter season, community, and beer. The event will take place in the evening from 5-10p.m. on Saturday, November 16, 2024, in Bend, Oregon.

07:45 EST Beamr Imaging reports deals worth $1.16M in revenues in Q4 'so far' - Beamr Imaging issued a Letter to Shareholders from Sharon Carmel, CEO which read in part, "In 2024, Beamr has strengthened its market presence by participating in 7 leading trade shows and conferences during the year so far, including Mile High Video, GTC, NAB, SIGGRAPH, Oracle CloudWorld, IBC and Demuxed. During these events, Beamr executives delivered high-impact presentations to hundreds of industry professionals, showcasing our innovative technology and expanding SaaS solutions. Furthermore, we held over 100 face-to-face meetings with existing and prospective customers. These efforts focused on differentiating Beamr in the video market and highlighting the value of our high-quality, high-efficiency, GPU-accelerated SaaS offerings to key and prospective customers in emerging markets, such as Media & Entertainment, User-Generated content and Internet-of-Things. We achieved a significant milestone with our first cloud sale, demonstrating that all of Beamr SaaS' components - ranging from onboarding and connecting the customers' video repositories to billing - are functioning as designed. Currently, we are working on dozens of new leads and deals in our sales funnel, which we are aiming to convert into signed customers in the end of 2024 and leading into 2025. Though we still cannot give projections, we are encouraged by the substantial interest generated since the launch of Beamr Cloud in February 2024, and we are pleased with the progress we've made so far...During the period of nine months ended September 30, 2024, we generated approximately $1.5M in revenues, compared with $1.43M in the nine months ended September 30, 2023, representing a 5% increase, and as of September 30, 2024, we had approximately $16.6M of cash and cash equivalents. Historically Q4 is a relatively strong quarter with 2024 being no exception. So far in Q4-2024, we have deals worth approximately $1.16M in revenues. We can also share that we have been successful in increasing our license fees as we look into 2025."

07:43 EST Regeneron announces new, updated data from hematology pipeline at ASH - Regeneron Pharmaceuticals announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology, ASH, 2024 Annual Meeting, taking place from December 7-10 in San Diego, CA. The latest research advances demonstrate the potential of Regeneron's diverse pipeline, which aims to address unmet needs in ten types of blood cancers and disorders. These innovative and differentiated approaches include CD3 bispecific antibodies, costimulatory bispecific antibodies, and a pioneering combination of a monoclonal antibody and small interfering RNA, siRNA. Progress on the odronextamab development program will be featured in twelve abstracts. Among them are initial results in patients with previously untreated follicular lymphoma from Part 1 of the Phase 3 OLYMPIA-1 confirmatory trial, which consists of a non-randomized safety run-in followed by a randomized efficacy portion comparing odronextamab monotherapy to rituximab plus standard-of-care chemotherapies. Two oral presentations on the ELM-1 and pivotal ELM-2 trials will feature new analyses in settings with significant unmet needs: one in patients with diffuse large B-cell lymphoma who progressed after CAR-T therapy and the other in relapsed/refractory marginal zone lymphoma.

07:40 EST Patterson Dental Supply extends strategic relationship with PDS Health - Patterson Dental Supply, a subsidiary of Patterson Companie announced an agreement in principle between Patterson and PDS Health, a leading dental and medical support organization formerly known as Pacific Dental Services, to extend their strategic relationship through the end of 2027. The extension allows Patterson to continue as the premier distributor for all merchandise, services, technology and core equipment across PDS Health's network of more than 1,000 supported practices nationwide. "Our mission is to be the most trusted business partner within the dental industry," said Don Zurbay, Patterson Companies president and chief executive officer. "We are proud to continue strengthening our relationship with PDS Health, providing new products, technology and services that streamline operations, optimize efficiency and maximize profitability. PDS Health has trusted Patterson Dental for more than 25 years and has established itself as a true leader in dentistry. That shared passion and focus for our industry has inspired us to grow together, and our longevity is a testament to the enduring partnership and shared vision for the future of healthcare."

07:39 EST Plug Power hosts 2024 Plug Symposium - Plug Power is hosting its sixth annual Plug Symposium at the Company's Vista headquarters and manufacturing facility in Slingerlands, N.Y. With the theme "Plug Doing Real Things," this year's event underscores Plug's role in driving the global green hydrogen economy, showcasing its comprehensive portfolio of deployed solutions worldwide. In addition, the Plug executive team will lay the groundwork for growth over the next five years. This event features presentations from CEO Andy Marsh and other top executives, as well as panel discussions that underscore Plug's role in the worldwide green hydrogen economy spanning policy, energy, applications, and technology. 2024 Milestones: Expanded Hydrogen Production: Commissioned a 15 TPD hydrogen plant in Georgia and upgraded a 10 TPD facility in Tennessee, strengthening Plug's leadership in U.S. green hydrogen production. Record Electrolyzer Deployments: Deployed electrolyzers on five continents, including a 100 MW system for Galp. Major Customer Deliveries: Delivered initial liquid green hydrogen supplies to Walmart, Amazon, and Home Depot, and launched stationary power sites across the U.S. Technological Advancements: Launched next-gen PEM electrolyzers and a mobile refueler, enabling rapid hydrogen deployment for fleet vehicles. Strategic Global Partnerships: Formed key alliances with bp, Iberdrola, and Allied Green Ammonia to expand hydrogen infrastructure worldwide. 2025 and Beyond: As Plug looks toward 2025, the Company remains laser-focused on several key priorities to drive sustainable growth and profitability. Plug's Energy Business: Targeting ~30% CAGR from 2025 to 2030, with revenue growth expected to be largely driven by its electrolyzer and cryogenic solutions. Plug's Applications Business: Targeting ~30% CAGR from 2025 to 2030 by expanding middle market opportunities in Material Handling, reaccelerating growth with pedestal customers, and driving sales of the Company's large-scale stationary product. Plug's Technology Roadmap: Targeting product improvements in performance, efficiency, and cost by focusing on research, development and design that impacts the commercial strategy and economical viability of the products and supports customers' use of the products. Plug's Approach to Policy: Navigating the shifting domestic and global political landscape that is creating both challenges and opportunities for businesses in the clean energy sector and leveraging hydrogen's unique position in the U.S. political environment with historically bipartisan support for its role in creating jobs, promoting manufacturing competitiveness, and contributing to energy and national security to drive policy changes that are beneficial to the hydrogen industry.

07:37 EST Kratos Defense awarded $116.7M prime contract to create, operate AFCGI - Kratos Defense & Security announced that it has been awarded a contract valued at a maximum of $116.7 million over five years to create and operate an Advanced Fire Control Ground Infrastructure, AFCGI, for the U.S. Space Development Agency's, SDA, Advanced Fire Control, AFC, program. The AFC will deliver integrated space and ground elements to demonstrate advanced fire control missions for missile defense.

07:36 EST Tilray's Breckenridge Brewery releases Candy Cane Vodka - Breckenridge Distillery releases its new Breckenridge Candy Cane Vodka for the holiday season. Whether enjoyed neat, on the rocks, or as the star ingredient of a favorite holiday cocktail, Breckenridge Distillery's Candy Cane Vodka brings holiday cheer to those aged 21 and up and is now available in retailers nationwide. Breckenridge Candy Cane Vodka is 80 proof / 40% ABV and is available in 750ml and 50ml. The red striped bottles will add a cheerful pop to your holiday tablescapes or make a sweet treat for cocktail lovers.

07:34 EST Unicycive Therapeutics expects cash to fund operations into 2026 - As of September 30, 2024, cash and cash equivalents totaled $32.3 million. The Company believes that it has sufficient resources to fund planned operations into 2026.

07:31 EST Zimmer Biomet names Arnold Schwarzenegger as Chief Movement Officer - Zimmer Biomet announced a partnership with Arnold Schwarzenegger, who will take on the newly established role of Chief Movement Officer. In this strategic role, Schwarzenegger will collaborate closely with Zimmer Biomet to motivate, engage and support individuals to increase mobility, maintain joint health and proactively incorporate movement into their daily routines to foster overall health and wellness.

07:27 EST Entero Therapeutics announces proposed reverse merger with Journey Therapeutics - Entero Therapeutics has entered into a binding term sheet for a reverse merger transaction with Journey Therapeutics. Upon completion of the Proposed Merger, the shareholders of Journey will acquire 99% of the equity of Entero. The combined company is expected to operate under the name Journey Therapeutics, Inc., and will apply for continued trading on The Nasdaq Capital Market. The completion of the Proposed Merger is subject to several conditions, including the negotiation of definitive agreements, the receipt by Entero of at least $5 million of equity financing, the effectiveness of a registration statement to be filed with the Securities and Exchange Commission and the approval of the stockholders of Entero. Following the completion of the Proposed Merger, the new entity would be under the leadership of Henry Ji, Ph.D., Chairman and Chief Executive Officer of Journey Therapeutics. It is contemplated that the combined company will prioritize advancing Journey's first-in-class, next-gen NIC product candidates targeting gynecological cancers, advanced non-Hodgkin's lymphoma and other difficult to treat cancers, alongside Entero's existing clinical assets. These existing assets include a latiglutenase, a pioneering oral biotherapeutic for celiac disease, adrulipase, a recombinant lipase enzyme for cystic fibrosis and chronic pancreatitis, and capeserod, a selective 5HT-4 receptor partial agonist, all of which would continue undergoing clinical development. Journey is a clinical-stage, biopharmaceutical company pioneering advanced cancer therapies that leverage nanotechnology and immunotherapy. Rivalling antibody-drug conjugates, its NIC platform is designed to target tumors precisely, delivering therapeutic agents directly to cancer cells with minimal impact on surrounding healthy tissue. By combining nanotechnology with immunoconjugates, Journey has developed technology that permits modular antibody-based targeting and tailored chemotherapeutic selection, potentially leading to more effective and less toxic treatment of a variety of cancer types. This innovative approach holds tremendous promise for the future of precision oncology. As described by the inventor, Svetomir N. Markovic, M.D., Ph.D., the NIC platform seeks to usher the next generation of antibody-drug complex therapeutics to enable simultaneous multi-drug delivery to multiple cancer targets. Early, Phase 1 clinical data with two prototype NICs engineered to treat end-stage metastatic ovarian/endometrial cancer or non-Hodgkin's lymphoma have shown highly encouraging results in clinical efficacy and safety.

07:22 EST PolyPid sees runway into 1Q25 - As of September 30, 2024, the Company had cash, cash equivalents, and short-term deposits in the amount of $9.5 million, compared to $5.3 million on December 31, 2023. PolyPid expects that its current cash balance will be sufficient to fund operations into the first quarter of 2025. If all warrants issued in both of the Company's most recent private placement financings are exercised, the Company would be funded into 2026.

07:15 EST Coterra to acquire assets of Franklin Mountain Energy, Avant Natural for $3.95B - Coterra Energy announced it has entered into two separate definitive agreements to acquire certain assets of Franklin Mountain Energy and Avant Natural Resources and its affiliates for aggregate consideration of $3.95B, consisting of $2.95B of cash and $1B of Coterra common stock, issued to one of the sellers, subject to certain purchase price adjustments. The cash portion of the consideration is expected to be funded through a combination of cash on hand and borrowings. The transactions are each subject to satisfaction of customary terms and conditions and are expected to close during the first quarter of 2025, with effective dates as of October 1. Neither acquisition is conditioned on the closing of the other acquisition. Coterra will fund the acquisitions with $2.95B of cash and the issuance of approximately 40.9M shares of Coterra common stock to certain sellers, which is valued at approximately $1B. The company plans to finance the cash portion of the purchase price through a combination of cash on hand and new borrowings.

07:12 EST Viracta Therapeutics expects cash to fund operations into Q1 of 2025 - Cash, cash equivalents, and short-term investments totaled approximately $21.1 million as of September 30, 2024, which Viracta expects will be sufficient to fund operations late into the first quarter of 2025.

07:09 EST Radcom names Benny Eppstein as new CEO, effective December 1 - Radcom (RDCM) announced the appointment of Benny Eppstein as its new CEO, effective December 1. Eppstein is a seasoned telecom industry veteran with a distinguished track record at Ericsson and Amdocs. He is a U.S. resident with over 20 years of sales experience working with tier-one telecom operators in North America and Japan. Eppstein held several leadership positions while at Amdocs (DOX), culminating in his role as General Manager and Division President for Canada.

07:07 EST Fulcrum Therapeutics expects cash to fund operations into at least 2027 - Based on its current operating plans, Fulcrum expects to end 2024 with approximately $240.0 million of cash, cash equivalents, and marketable securities, and expects its cash burn for the full year 2025 will be approximately $55.0 million to $65.0 million. Fulcrum also expects that its cash, cash equivalents, and marketable securities as of September 30, 2024 will be sufficient to fund its current operating requirements into at least 2027.

07:06 EST Seres Therapeutics expects cash to fund operations into Q4 of 2025 - As of September 30, 2024, Seres had $66.8 million in cash and cash equivalents. Based on existing cash, projected installment payments to be received from Nestle Health Science in 2025, transaction-related obligations and current operating plans, the Company expects to fund operations into the fourth quarter of 2025.

07:02 EST Acrivon Therapeutics sees cash runway into 2H26 - As of September 30, 2024, the company had cash, cash equivalents and marketable securities of $202.8 million, which is expected to fund our operating expenses and capital expenditure requirements into the second half of 2026.

06:56 EST TreeHouse renews $400M share repurchase program - TreeHouse announced that its board of directors has approved a $400M share repurchase authorization. This renewal maintains the existing annual cap of $150M. The company said it will repurchase shares opportunistically and the authorization is open ended. The company can begin repurchasing shares immediately.

06:48 EST Gilead reports results from pivotal Phase 3 PURPOSE 2 trial - Gilead Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying twice-yearly lenacapavir, the company's injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. Newly presented results include data on adherence to and pharmacokinetics of lenacapavir among trial participants. The data were presented during an oral abstract session at the International Congress on Drug Therapy in HIV Infection and will be published in The New England Journal of Medicine. The release of the full PURPOSE 2 data follows the unblinding of the trial at interim analysis in September and a presentation of additional efficacy and safety data last month at the HIV Research for Prevention Conference in Lima, Peru. Those previously reported data showed that lenacapavir reduced HIV infections by 96% compared to background HIV incidence, or bHIV, with two incident cases among 2,179 participants, corresponding to 99.9% of participants not acquiring HIV infection in the lenacapavir group. Twice-yearly lenacapavir also demonstrated superiority to once-daily Truvada for pre-exposure prophylaxis (PrEP) and was generally well-tolerated, with no significant or new safety concerns identified. Adherence to lenacapavir and to the placebo injections that were part of the oral PrEP study group was high: 91.0% of all trial participants received on-time injections at week 26, and 92.8% of participants received on-time injections at one year. Lenacapavir reduced HIV infections by 96% compared to background HIV incidence. Truvada adherence was initially high but declined over time. In the Truvada group, nine incident HIV infections occurred, all in participants with low or no adherence. PURPOSE 2 is a Phase 3, double-blind, multicenter, randomized study evaluating the safety and efficacy of twice-yearly subcutaneous lenacapavir for PrEP versus bHIV and once-daily oral Truvada in 3,271 cisgender gay, bisexual, and other men, transgender women, transgender men, and gender non-binary individuals aged 16 years or older who have sex with partners assigned male at birth. Gilead continues to focus on global access strategies, including for low-, middle- and high-income countries.

06:36 EST Parsons selected for America's River Crossing project - Parsons announced that the Tennessee Department of Transportation has selected the company to serve as lead designer for the proposed America's River Crossing project, a pivotal infrastructure project aimed at enhancing transportation connectivity and economic growth in the Memphis region. This contract win marks a significant milestone for Parsons, further solidifying its position as a leader in long-span bridge design. The proposed America's River Crossing project will replace the existing 75-year-old I-55 bridge, which, by 2050, is projected to support approximately 64,000 vehicles carrying residents, workers, and freight moving between Tennessee, Arkansas, and Mississippi every day. Parsons is responsible for delivering a design to address route resiliency, improve safety, and maintain a state of good repair.

06:30 EST Supermicro says unable to file quarterly report on Form 10-Q in timely manner - Super Micro Computer announced that it is unable to file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 in a timely manner without unreasonable effort or expense. As previously announced, the company has been unable to file its Annual Report on Form 10-K for the period ended June 30, 2024. As previously disclosed, in response to information that was brought to the attention of the Audit Committee of the company's Board of Directors, the Board of Directors formed a committee to review certain of the company's internal controls and other matters. As disclosed in the company's Form 8-K filed on October 30, 2024, prior to the completion of the Review, the company's independent registered public accounting firm at the time resigned. The company is diligently working to select an independent registered public accounting firm. The Special Committee has completed its investigation based on a set of initial concerns raised by the Former Firm. The Special Committee has other work that is ongoing, but expects the Review to be completed soon. Additional time is also needed for: (i) the company to select and engage a Successor Firm, (ii) the company's management to complete its assessment of the effectiveness of its internal controls over financial reporting as of June 30, 2024, and (iii) the Successor Firm to conduct its audit of the financial statements to be incorporated in the 2024 Form 10-K and conduct its audit of the company's internal controls over financial reporting as of June 30, 2024. Further additional time is needed for the company to prepare the Q1 2025 Form 10-Q and for the Successor Firm to review the interim financial statements to be included in the Q1 2025 Form 10-Q. The Q1 2025 Form 10-Q cannot be completed and filed until the 2024 Form 10-K is completed and filed. As a result of the foregoing, the company needs additional time to finalize the financial statements and related disclosures to be filed as part of the Delinquent Reports. Super Micro shares are down 3.4% in premarket trading.

06:14 EST X4 reports data from Phase 2 clinical trial evaluating mavorixafor - X4 Pharmaceuticals announced positive new clinical data from its now completed Phase 2 clinical trial evaluating mavorixafor, an oral CXCR4 antagonist, in the treatment of people with chronic neutropenia, or CN. An analysis of final data from the six-month study showed that once-daily oral mavorixafor durably and meaningfully increased participants' mean absolute neutrophil counts, or ANC. In addition, when tested in combination with injectable granulocyte colony-stimulating factor, or G-CSF, mavorixafor treatment enabled clinicians to substantially reduce G-CSF dosing while maintaining normal mean ANC levels. The Phase 2 study of mavorixafor was a six-month, open-label clinical trial that enrolled a total of 23 participants diagnosed with idiopathic, congenital, or cyclic chronic neutropenia. The analysis presented today includes results from the two study treatment groups: mavorixafor monotherapy and mavorixafor in combination with G-CSF. Consistent with previously presented analyses, results from participants receiving mavorixafor monotherapy showed that mavorixafor durably increased mean ANC from baseline, with mean ANC reaching normal levels at Month 3 and Month 6. Further analysis showed that those with severe CN achieved greater than two-fold increases in mean ANC levels out to six months, reaching levels typically targeted by physicians for patients with severe CN. Mavorixafor in combination with injectable G-CSF: New results presented demonstrated that physicians chose to reduce G-CSF dosing in nine of 12 eligible participants. Of those nine, eight had G-CSF reduced at the earliest timepoint permitted and three were taken completely off of G-CSF prior to their Month 6 visit. Mean reductions in G-CSF were 52% at Month 3 and 70% at Month 6, while mean ANC levels remained in the normal range. The three participants receiving mavorixafor who remained on stable doses of G-CSF maintained mean ANC levels in the normal range at all timepoints. X4 also announced new findings from a sub-study comparing the mean percentage of functional neutrophils in samples from healthy donors to participants from the Phase 2 CN study using two common study methods. These results demonstrated that the mean percentage of functional circulating neutrophils in CN participants in this sub-study was comparable to that of healthy donors after six months of mavorixafor dosing. The subset of participants with congenital neutropenia also had mean percentage of functional neutrophils comparable to those of healthy donors.

06:10 EST Bellevue Capital Partners acquires additional 100,000 shares of Global Net Lease - Bellevue Capital Partners, one of the largest shareholders of Global Net Lease, announces the acquisition of an additional 100,000 shares of GNL. This strategic investment reemphasizes Bellevue Capital Partners' confidence in the company's management and its execution of its previously announced strategic plan. Bellevue Capital Partners is encouraged by GNL's recent communications regarding its strategic disposition plan, which includes the recently announced $950M in asset sales this year at a cap rate of 7.1%. The execution of this strategy is a testament to GNL and its management team's ability to navigate market conditions effectively and execute on their announced strategy. The continued, demonstrated execution of their disposition strategy at competitive cap rates informs our strong belief in the company's vision and strategic direction. As one of GNL's largest shareholders, Bellevue Capital Partners remains committed to supporting management in its efforts to drive performance and create value.

06:04 EST Palantir renews multi-year enterprise agreement with Rio Tinto - Palantir (PLTR) has renewed its multi-year enterprise agreement with the Rio Tinto (RIO). The agreement extends the enterprise agreement for an additional four years and secures Rio Tinto's ongoing access to the Palantir Artificial intelligence Platform, or AIP. As an early adopter of Palantir Foundry, Rio Tinto has already primed its operational landscape for the deployment of AI through the creation of a digital twin. Via the Ontology, AIP will enable Rio Tinto to build, test, and validate AI use cases at an accelerated pace and deploy them to production safely.

05:17 EST Halliburton to open new facilities in Namibia - Halliburton will open new facilities in Namibia highlighting the importance of the country's growing oil and gas industry. The facilities, which will support the company's in-country operations, are located in Windhoek, Walvis Bay, Swakopmund, and Luderitz. With a combined footprint of 20,000 m, the facilities create a presence in the region. The Windhoek office will handle support services, while the Walvis Bay facility will focus on Cementing & Drilling Fluids services and warehousing. Swakopmund will house Sperry Drilling, Well Completions, Testing & Subsea, and Wireline & Perforating services. Luderitz will support Cementing and Wireline operations. Through these locations, Halliburton will deliver advanced technologies that include oilfield automation and remote operations, geosteering, measurement while drilling, and well testing to Namibia's energy sector.